×
0 0 0 0 0 0 0 0
Stockreport

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California

MEDICINOVA (MNOV)  More Company Research Source: GlobeNewswire
Last medicinova earnings: 2/13 04:34 pm Check Earnings Report
PDF LA JOLLA, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s completed clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis) has been accepted for presentation at the American Academy of Neurology (AAN) 70th Annual Meeting to be held April 21-27, 2018 in Los Angeles, California. The presentation entitled "Ibudilast – Phosphodiesterase Type 4 Inhibitor – Bi-Modal Therapy with Riluzole in Early [Not Requiring Non-Invasive Ventilation (NIV )] Cohort (EC) and Advanced [Requiring NIV] (ANC) Amyotrophic Lateral Sclerosis (ALS) Patients - Single-Center Adaptive Design Six-Month Double-Blind (DB) - Placebo-Controlled Phase 1b/2a Epoch Followed by Six-Month Open Label Extension (OLE) Epoch, Washout (WO) and Post-Washout Epoch (PWO) - Final Report and Future Di [Read more]

IMPACT SNAPSHOT EVENT TIME: MNOV
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS